Pfizer provides FDA vaccine data from kids ages 5-11
NEW YORK — Pfizer has submitted research to the U.S. Food and Drug Administration on the effectiveness of its COVID-19 vaccine in children as it moves closer to seeking approval for expanded use of the shots.
The drugmaker and its partner, Germany’s BioNTech, say they expect to request emergency use authorization of their vaccine in children ages 5 to 11 “in the coming weeks.” The companies also plan to submit data to the European Medicines Agency and other regulators.
The two-shot Pfizer vaccine is currently available for those 12 and older. An estimated 100 million people in the U.S. have been fully vaccinated with it, according to the Centers for Disease Control and Prevention.
Pfizer tested a lower dose of the shots in children. The drugmaker said last week that researchers found the vaccine developed coronavirus-fighting antibody levels in children that were just as strong as those found in teenagers and young adults getting regular-strength doses.
Earlier this month, FDA chief Dr. Peter Marks told the AP that once Pfizer turns over its study results, his agency would evaluate the data “hopefully in a matter of weeks” to decide if the shots are safe and effective enough for younger kids.
Another U.S. vaccine maker, Moderna, also is studying its shots in elementary school-aged children. Results are expected later in the year.
See all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic
Today’s Top Stories
- SLCPD shuts down area near 700 East following fight at yoga studio
- Two people injured in Brigham City two-vehicle crash
- Utah’s GOP Congressmen defeat primary challengers
- Sen. Mike Lee fends off 2 opponents to win Utah GOP primary
- Breyer makes it official: He’s leaving the Supreme Court on Thursday at noon
- Different abortion law now in effect in Utah
- Church of Jesus Christ of Latter-day Saints reacts to Roe v. Wade
- Remaining deer, elk permits can be purchased in July
- Bountiful woman arrested after allegedly stealing $6,000 from patient
- Intermountain Healthcare study finds “better” IV fluid treatment